<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-92179</identifier>
<setSpec>0034-947X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hydrocarbonate alteration in cystic fibrosis</dc:title>
<dc:description xml:lang="en">Cystic fibrosis-related diabetes mellitus (CFRD) is the leading comorbidity reported in Cystic Fibrosis (CF), its prevalence increases with age. More than 50% of patients with CF have diabetes by age 30 years. CFRD is associated with increased mortality rates with accelerated deterioration of lung function and nutritional status. The cause of CFRD is believed to be the result of pancreatic islet dysfunction caused by inflammation and fibrosis as a consequence of viscid exocrine secretions. Los of insulin-producting b cells in the pancreas leads to a progressive insulinopenia. On the other hand, patients with CFRD have also been reported to have peripheral insulin resistance. There is often a long and asymptomatic prediabetic period of up 4 years before CFRD is detected. Oral glucose tolerance testing is currently the most sensitive method for detecting CFRD. However, the continuous glucose monitoring system is a new tool that is accurate to detect more glucose fluctuations. When pharmacological treatment is indicated, insulin therapy is the first choice. Initially, short-acting insulin with meals, and when fasting hyperglycemia appears a long acting insulin analog should be added (AU)</dc:description>
<dc:creator>Martín Frías, M</dc:creator>
<dc:creator>Barrio Castellanos, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La alteración del metabolismo hidrocarbonado es una complicación frecuente e importante de la Fibrosis Quística. Se expresa, en general, al final de la segunda década de la vida y llega a afectar a más del 50% de los pacientes mayores de 30 años. Su desarrollo incrementa la morbilidad (disminución de la función pulmonar, aumento de las infecciones y pérdida ponderal) y la mortalidad. La causa fundamental es la insulinopenia, aunque también interviene la insulina resistencia. El diagnóstico se basa en la sobrecarga oral de glucosa, que debe hacerse anualmente a partir de la pubertad debido a que durante mucho tiempo se mantienen niveles normales de glucemia en ayunas. La monitorización continua de glucosa puede ayudar a un diagnóstico y tratamiento más precoz. El tratamiento se basa en el aporte de insulina rápida prepandial adaptado a la ingesta y cuando existe hiperglucemia en ayunas, se precisa añadir un análogo de insulina de acción prolongada (AU)</dc:description>
<dc:source>Rev Esp Pediatr;66(4): 211-217, jul.-ago. 2010.</dc:source>
<dc:identifier>ibc-92179</dc:identifier>
<dc:title xml:lang="es">Alteración hidrocarbonada en la fibrosis quística</dc:title>
<dc:subject>^d22231^s22031</dc:subject>
<dc:subject>^d6096^s22074</dc:subject>
<dc:subject>^d3568^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2278^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201008</dc:date>
</metadata>
</record>
</ibecs-document>
